The heart is a muscle like no other, beating 60 to 100 times per minute on average, around the clock. But when it grows weak, it can lead to serious problems: from debilitating shortness of breath and ...

Whether revascularization by percutaneous coronary intervention (PCI) can improve event-free survival and left ventricular function in patients with severe ischemic left ventricular systolic ...

Heart failure sounds alarming—and rightfully so. Yet approximately 6.5 million Americans currently live with this condition, many with the specific variant called systolic heart failure, and a ...

The drug is now expected to be available in the U.S. in the second half of January 2026. ・The prescribing information for the ...

FDA approved CYTK's Myqorzo for oHCM. It reduces heart's pumping ability, has a warning for heart failure and expected to ...

In patients with severe left ventricular systolic dysfunction on optimal medical therapy for HF, undergoing PCI did not improve rates of all-cause death or HF hospitalization, according to the results ...

Cytokinetics has announced that the US Food and Drug Administration (FDA) has approved MYQORZO (aficamten) tablets in 5mg, ...

M ore than 6 million adults in the United States have heart failure. Of these, about half have diastolic heart failure and the other half have systolic heart failure. In February 2021, the U.S. Food ...

It is a common perception that approximately 50% of heart failure (HF) patients present with a normal or near-normal left ventricular (LV) ejection fraction ("HF with preserved systolic function"), ...

MYQORZO, a Cardiac Myosin Inhibitor, Directly Addresses Underlying Hypercontractility Associated with Obstructive HCM FDA ...